Testare l'aggiunta della terapia virale antitumorale Telomelysin™ alla chemioradioterapia per i pazienti con carcinoma esofageo avanzato e non candidati all'intervento chirurgico
Studio di fase I con coorte di espansione di OBP-301 (Telomelysin™) e chemioradioterapia definitiva per pazienti con carcinoma esofageo e gastroesofageo localmente avanzato che non sono candidati alla chirurgia
This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Stadio clinico III Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Adenocarcinoma della giunzione gastroesofagea non resecabile
- Terapia postneoadiuvante Fase III Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Terapia postneoadiuvante Fase IIIA Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Terapia postneoadiuvante Fase IIIB Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio clinico II Adenocarcinoma esofageo AJCC v8
- Stadio clinico IIA Adenocarcinoma esofageo AJCC v8
- Stadio clinico III Adenocarcinoma esofageo AJCC v8
- Adenocarcinoma esofageo in stadio patologico II AJCC v8
- Stadio patologico IIA Adenocarcinoma esofageo AJCC v8
- Adenocarcinoma esofageo in stadio patologico IIB AJCC v8
- Adenocarcinoma esofageo in stadio patologico III AJCC v8
- Stadio patologico IIIA Adenocarcinoma esofageo AJCC v8
- Adenocarcinoma esofageo in stadio patologico IIIB AJCC v8
- Carcinoma spinocellulare
- Stadio clinico II Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio clinico IIB Adenocarcinoma esofageo AJCC v8
- Adenocarcinoma avanzato della giunzione gastroesofagea
- Cancro a cellule squamose
- Stadio patologico III Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio patologico IIIA Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio patologico IIIB Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Terapia postneoadiuvante Stage III Adenocarcinoma esofageo AJCC v8
- Terapia postneoadiuvante Stadio IIIA Adenocarcinoma esofageo AJCC v8
- Terapia postneoadiuvante Stadio IIIB Adenocarcinoma esofageo AJCC v8
- Stadio clinico IIA Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio clinico IIB Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio patologico II Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio patologico IIA Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Stadio patologico IIB Adenocarcinoma della giunzione gastroesofagea AJCC v8
- Adenocarcinoma esofageo avanzato
- Terapia postneoadiuvante Stage II Adenocarcinoma esofageo AJCC v8
- Terapia postneoadiuvante Fase II Adenocarcinoma della giunzione gastroesofagea AJCC v8
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.
SECONDARY OBJECTIVES:
I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.
II. To assess the number of clinical complete responses (cCR).
III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.
EXPLORATORY OBJECTIVE:
I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.
OUTLINE:
This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.
Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
California
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
South Pasadena, California, Stati Uniti, 91030
- City of Hope South Pasadena
-
Upland, California, Stati Uniti, 91786
- City of Hope Upland
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Moffitt Cancer Center
-
-
Kansas
-
Fairway, Kansas, Stati Uniti, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Stati Uniti, 66160
- University of Kansas Cancer Center
-
Westwood, Kansas, Stati Uniti, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Stati Uniti, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Stati Uniti, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Stati Uniti, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Stati Uniti, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Stati Uniti, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration
- Gastroesophageal junction tumors must be Siewert type I/II
-
Required diagnostic workup for study entry:
- History/physical examination prior to registration
- Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
- Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
- Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
- Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration
-
Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)
-
Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)
-
AST/ALT ≤ 2.5 x ULN
-
Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;
-
Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures
-
Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months
-
Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device
-
The patient must provide study-specific informed consent prior to study entry
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial
Exclusion Criteria:
-
Definitive clinical or radiologic evidence of metastatic disease including:
- Positive malignant cytology of the pleura, pericardium or peritoneum
- Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
- Tracheoesophageal fistula
- Radiographic evidence of distant organ involvement
- Non-regional lymph nodes that cannot be contained within a radiation field
-
More than 1 esophageal lesion
-
Prior systemic chemotherapy for the study cancer
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis
-
For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse
-
Uncontrolled diabetes
-
Infection requiring IV antibiotics at the time of registration
-
Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry
-
Received live vaccine within 30 days prior to registration
-
Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab
-
Breast feeding females
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (OBP-301, carboplatin, paclitaxel, radiation)
Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity. |
Intravenously (IV)
Altri nomi:
Intravenously (IV)
Altri nomi:
Daily fractions
Altri nomi:
Intra-tumoral injection
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
Lasso di tempo: From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:
If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL). |
From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di partecipanti vivi a 1 e 2 anni
Lasso di tempo: A 1 e 2 anni
|
A 1 e 2 anni
|
|
|
Number of Participants by Highest Grade Adverse Event Reported
Lasso di tempo: From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
|
Number of Participants With Clinical Complete Response (cCR)
Lasso di tempo: 6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:
|
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
|
Number of Participants Alive Without Progression at 1 and 2 Years
Lasso di tempo: At 1 and 2 years
|
Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease. |
At 1 and 2 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Geoffrey Y Ku, NRG Oncology
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Carcinoma, cellule squamose
- Neoplasie, cellule squamose
- Prodotti chimici organici
- Terapie
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Fenomeni fisici
- Complessi di coordinamento
- Taxoidi
- Ciclodecani
- Diterpenes
- Economia e organizzazioni sanitarie
- Economia
- Carboplatino
- Paclitaxel
- Radioterapia
- Radiazione
- Tasse
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NRG-GI007
- U10CA180868 (Sovvenzione/contratto NIH degli Stati Uniti)
- NRG-GI007 (Altro identificatore: CTEP)
- NCI-2020-02320 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- NRG-GI007 (Altro identificatore: NRG Oncology)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .